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Abstract Frontotemporal lobar degeneration (FTLD) is a
clinically, genetically and pathologically heterogeneous
disorder. Within FTLD with ubiquitin-positive inclusions
(FTLD-U), a new pathological subtype named FTLD-FUS
was recently found with fused in sarcoma (FUS) positive,
TDP-43-negative inclusions, and striking atrophy of the
caudate nucleus. The aim of this study was to determine the
frequency of FTLD-FUS in our pathological FTLD series,
and to describe the clinical, neuroimaging and neuro-
pathological features of FTLD-FUS, especially caudate
atrophy. Demographic and clinical data collected pro-
spectively from 387 patients with frontotemporal dementia
(FTD) yielded 74 brain specimens. Immunostaining was
carried out using a panel of antibodies, including AT-8,
ubiquitin, p62, FUS, and TDP-43. Cortical and caudate
atrophy on MRI (n = 136) was rated as normal, mild-
moderate or severe. Of the 37 FTLD-U cases, 33 were
reclassified as FTLD-TDP and four (0.11, 95%: 0.00–0.21)
as FTLD-FUS, with ubiquitin and FUS-positive, p62 and
TDP-43-negative neuronal intranuclear inclusions (NII).
All four FTLD-FUS cases had a negative family history,
behavioural variant FTD (bvFTD), and three had an age at
onset B40 years. MRI revealed mild-moderate or severe
caudate atrophy in all, with a mean duration from onset till
MRI of 63 months (range 16–119 months). In our total
clinical FTD cohort, we found 11 patients (0.03; 95% CI:
0.01–0.05) with bvFTD, negative family history, and age at
onset B40 years. Caudate atrophy was present in 10 out of
136 MRIs, and included all four FUS-cases. The newly
identified FTLD-FUS has a frequency of 11% in FTLD-U,
and an estimated frequency of three percent in our clinical
FTD cohort. The existence of this pathological subtype can
be predicted with reasonable certainty by age at onset
B40 years, negative family history, bvFTD and caudate
atrophy on MRI.
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Introduction
Frontotemporal dementia (FTD) is the second most com-
mon type of presenile dementia, and a clinically, geneti-
cally and pathologically heterogeneous disorder [1, 2].
Behavioural changes and cognitive dysfunctions, espe-
cially language, are core clinical features. Four clinical
subtypes can be distinguished: the behavioural variant of
FTD (bvFTD), semantic dementia (SD), progressive non-
fluent aphasia (PNFA), and FTD with motor neuron disease
(FTD-MND).
Frontotemporal lobar degeneration (FTLD) is the com-
mon underlying pathology of all four clinical variants, and
can be divided into FTLD with tau-positive immunoreac-
tive inclusions (FTLD-tau) and FTLD with ubiquitin-
positive immunoreactive inclusions (FTLD-U). After the
TDP-43 protein was found to be the major constituent of
ubiquitin-positive inclusions [3], the latter term was chan-
ged to FTLD-TDP. However, the identification of TDP-43-
negative inclusions in some FTLD-U cases has resulted in
the designation of a new neuropathological subtype, atyp-
ical FTLD-U [4–6]. Very recently, the name of this subtype
has been changed into FTLD-fused in sarcoma (FTLD-
FUS) by the observation of positive staining of these
inclusions with antibody against FUS protein [7].
The characteristic features of FTLD-FUS are an early-
onset FTD with severe progressive psychobehavioural
changes, a negative family history and striking atrophy of
the striatum at neuropathological examination [4–7]. Its
exact frequency is yet unknown, and neuroimaging features
may differentiate it from other subtypes during life. The
aim of this study was to determine the frequency of FTLD-
FUS in our FTLD-U cases and to describe the clinical,
neuroimaging and neuropathological features of FTLD-
FUS. Furthermore, we estimated the prevalence of FTLD-
FUS in our clinical cohort of FTD on the basis of a
combination of specific clinical features.
Methods
Patients with FTD were ascertained in an ongoing genetic-
epidemiologic study conducted in The Netherlands since
1994 [1, 8, 9], after referral to the out-clinic department of
the Erasmus Medical Center, or after a visit in nursing
homes and psychogeriatric hospitals by the research phy-
sician. Detailed clinical history was obtained from the
spouses and first-degree relatives using a checklist of
behavioural and cognitive changes, and motor neuron signs.
The age at onset was defined as the age at which the first
symptom compatible with FTD diagnosis was observed by
a close relative or caretaker [1, 9]. During the neurological
examination carried out in all patients, special attention was
paid to the presence of extrapyramidal and motor neuron
disease signs. Data on family history were provided by a
spouse or first-degree relative using a structured question-
naire. Family history was defined as positive if patients had
at least one-first-degree relative with dementia, parkinson-
ism, or MND, irrespective of their age of onset.
Neuropsychological evaluation consisted of tests for
memory functions (Rey figure, 15-Word test [10]), atten-
tion and concentration, executive functions (Stroop, Trail-
making A and B, Wisconsin Card Sorting Test, WAIS
subtest substitution), language (Boston Naming Test, the
Dutch revised version of the Semantic association test
[11]), and visuoconstructive and visuospatial skills (Clock
drawing, Block design of the WAIS), and was performed in
a subset of patients at our out-clinic department. Due to the
variation in test batteries, a detailed comparison between
subgroups was not possible. Severity of dementia at
ascertainment was assessed using the Clinical Dementia
Rating scale [12].
MRI scans performed between 1990 and 2008 were
available for evaluation in 136 out of 387 patients. Avail-
able T1-weighted MR, T2-weighted MR, Proton-density
(PD) weighted MR, and fluid attenuated inversion recovery
(FLAIR) MR images were used for evaluation.
The severity of cortical and caudate atrophy on MRI was
evaluated and semi-quantitatively rated according to a
three-point scale: (0) normal caudate nucleus; (1) mild or
moderate atrophy of the caudate nucleus, either still bulg-
ing into the lateral ventricle or with a flat contour;
(2) severe atrophy with no visible caudate nucleus. The
presence of caudate atrophy was evaluated by a radiologist
and neurologist blinded to clinical and pathological find-
ings. Disagreement was solved by consensus.
Mutation screening of all exons and exon–intron regions
of MAPT, GRN and CHMP2B genes was performed in all
patients with a positive family history, and in a subset of
patients with sporadic FTD (n = 72) as previously
described [1, 9].
Two hundred thirty-two patients died during a follow up
period of 14 years, of which 74 patients underwent brain
autopsy. Brain autopsy was carried out within four hours of
death according to the Legal and Ethical Code of Conduct
of The Netherlands Brain Bank. Macroscopic inspection of
the brain included the frontal, temporal, parietal, and
occipital lobes, cerebellum, hippocampus, basal ganglia
and substantia nigra.
Tissue blocks were taken from all cortical areas,
hippocampus, amygdala, basal ganglia, substantia nigra,
pons, medulla oblongata, cerebellum, and cervical spinal
cord. They were embedded in paraffin blocks and subjected
to routine staining with haematoxylin-eosin, Bodian,
methenamine-silver, and Congo red. The severity of neu-
ron loss was scored as absent, mild, or moderate-severe.
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Immunohistochemistry was performed with antibodies
directed against: hyperphosphorylated tau (AT-8, Innoge-
netics, Ghent, Belgium; 1:400); ubiquitin (anti-ubiquitin,
DAKO, Glostrup, Denmark; 1:500, following 80C antigen
retrieval); b-amyloid protein (anti-beta amyloid, DAKO,
Glostrup, Denmark; 1:100, following formic acid pre-
treatment); a-synuclein (anti-a-synuclein; Zymed Labora-
tories, San Francisco, California, USA; undiluted, following
formic acid pre-treatment); poli-ubiquitin-binding protein
p62 (BD Biosciences Pharmingen, San Diego, CA, USA;
1:200, following pressure cooking); TDP-43 (Biotech,
Chicago, IL, USA; 1:100, following pressure cooking); and
a–internexin (anti-alpha-internexin, Invitrogen, Camarillo,
CA, USA, 1:100, following pressure-cooking), FUS
(Sigma-Aldrich anti-FUS; 1:25–1:200 with initial over-
night incubation at room temperature, following pressure
cooking).
Antigen retrieval was done either for 30 min in 0.1 M
sodium citrate buffer at 80C and pH 7.7 or using pressure
cooking in 0.1 M sodium citrate buffer (pH 6) for 5 min.
Pre-treatment with 70% formic acid was done for 5 min
(a-synuclein and b-amyloid).
Primary antibodies were incubated overnight at 4C.
Endogenous peroxidase activity was inhibited by incuba-
tion for 30 min in PBS-hydrogen peroxide-sodiumazide
solution (100 ml 0,1 M PBS ? 2 ml 30% H2O2 ? 1 ml
natriumazide). The Histostain-Plus broad-spectrum kit
DAB (Zymed, San Francisco, California, USA) was used
and slides were counterstained with Mayer’s haematoxylin
and mounted in entellan.
Neuropathological examination of brains from the 74
autopsied patients with clinical FTD revealed 70 brains
with FTLD (FTLD-U in 37, FTLD-tau in 32 and FTLD
with no inclusions (FTLD-ni) in one), whereas familial
Creutzfeldt-Jakob disease (fCJD) was diagnosed in two
brains, and Alzheimer’s disease (AD) in the remaining
two.
The study was approved by the Medical Ethical Com-
mittee at the Erasmus MC-University Medical Center
Rotterdam. For each patient, a spouse or first-degree rela-
tive of the patient gave written informed consent.
Results
Thirty-three out of 37 FTLD-U cases (0.89; 95% CI: 0.79–
1.00) showed positive staining with the TDP-43 antibody
and were reclassified as FTLD-TDP, whereas four cases
had ubiquitin-positive, TDP-43-negative inclusions. All
four FTLD-U patients with TDP-43 negative inclusions
showed positive staining with the FUS antibody and were
designated as FTLD-FUS. Inclusions of FTLD-TDP cases
did not stain with the FUS antibody. FTLD-FUS was
present in 4 out of all 70 FTLD brains (0.06; 95% CI: 0.00–
0.11), and in four out of 37 FTLD-U cases (0.11; 95% CI:
0.00–0.21).
Table 1 Demographic, clinical and MRI features of FTLD-FUS cases
Case 1 Case 2 Case 3 Case 4
Gender Male Female Female Female
Onset (years) 49 30 32 35
Death (years) 59 46 41 45
Family history Negative Negative Negative Negative
FTD subtype BvFTD BvFTD BvFTD BvFTD
Prominent symptoms Sexual disinhibition
Visual hallucinations
Hyperorality
Obsessive–compulsive
Persecution delusions
Extreme parsimony
Shoplifting
Hyperorality
Apathy
Sexual disinhibition
Shoplifting
Hyperorality
Obsessive–compulsive
Parsimony
Shoplifting
Neurological examination No abnormality Mild cogwheeling left No abnormality No abnormality
Neuropsychological
evaluation
Attention
and concentration ;
Executive functions ;
Memory ;
Perseverations
Attention
and concentration ;
Executive functions ;
Perseverations
Impulsive stereotypical
Attention
and concentration ;
Executive functions ;
Mild memory ;
Attention
and concentration ;
Executive functions ;
Impulsive
CDRa 3 3 2 3
MRI FT?? F? T?? F? FT??
Cau?? Cau?? Cau? Cau??
a Clinical dementia rating scale at ascertainment; F frontal, T temporal, Cau caudate, ? mild-moderate atrophy, ?? severe atrophy
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Demographic and clinical data for FTLD-FUS
Demographic and clinical data of the four patients with
FTLD-FUS are presented in Table 1. All four patients had
clinical bvFTD and a negative family history, and three out
of four patients had an age at onset before the age of 40. The
presenting symptoms varied among these four cases. Two
patients presented with obsessive–compulsive behaviour, in
particular showing extremely parsimonious behaviour.
Case 1 and Case 3 showed sexually disinhibited behaviour
(Case 1 frequently visited prostitutes, while married). Three
out of four patients shoplifted several shops, especially the
two patients who presented with obsessive–compulsive
behaviour. Hyperorality has developed in all four patients,
and was the presenting symptom in three patients. Visual
hallucinations of deformed paintings were mentioned in the
case of one patient, and persecution delusions in another.
All patients developed language problems later in the
course of the disease, with economy of utterances in all,
perseverations (n = 3), echolalia (n = 2), stereotypy
(n = 2) and eventually mutism in all. Neurological exam-
ination was unremarkable without signs of motor neuron
disease, pyramidal or extrapyramidal dysfunction, except
for mild left-sided cogwheeling in one patient.
Neuropsychological testing revealed impaired attention
and concentration, and executive deficits, with normal
orientation, memory and visuoconstructive functions in all
four patients, except for evident memory problems in one.
MRI showed severe frontal and/or temporal atrophy in
three patients, and mild to moderate frontal atrophy in one.
All four patients had mild-moderate (n = 1), or severe
caudate atrophy (n = 3), at a mean duration of illness of
63 months (range 16–119 months) (Figure 1). Genetic
screening revealed no mutations in MAPT or GRN in all
four patients, and in CHMP2B genes in three patients.
DNA was not available anymore in Case 1 to screen for
CHMP2B gene mutations.
Age at onset B40 years, negative family history,
and behavioural variant FTD
The frequency of FTLD-FUS in our clinical cohort was
estimated by using negative family history, age at onset
B40 years and bvFTD as distinctive features for FTLD-
FUS patients. We selected patients with a negative family
history and bvFTD (n = 126). We stratified our patients
according to age at onset and made three subgroups: age at
onset B40 years (n = 11),[40 to B50 years (n = 23), and
[50 years (n = 92). FTLD-FUS was found in three out of
11 patients (0.27) in the group with age at onset B40 years,
one out of 23 (0.04) in the group of patients with age at
onset[40 to B50 years, and was absent in the group of 92
patients with age at onset [50 years. FTLD-FUS is not
more frequently found in patients with an age at onset B40,
than in patients with an age at onset [40 to B50 years
(Fisher’s Exact Test, p = 0.089). However, FTLD-FUS is
more frequently found in patients with an age at onset
B40 years than in patients with an age at onset [50 years
(Fisher’s Exact Test, p = 0.001).
The estimated prevalence of FTLD-FUS for the total
clinical FTD group based on family history, age at onset
B 40 years and bvFTD as clinical subtype, is 11 out of 387
patients (0.03; 95% CI: 0.01–0.05).
Caudate atrophy
Severe caudate atrophy is one of the pathological hallmarks
of FTLD-FUS. We reviewed all available MRIs of all
clinical FTD patients (n = 136) for the presence of caudate
atrophy. Caudate atrophy was present in 10 out of 136
MRIs (0.07; 95% CI: 0.03–0.12). Seven of these 10
patients had a negative family history, onset B40 years and
bvFTD, of whom three had pathological proven FTLD-
FUS. Pathology was not available in the other four cases.
Of the remaining three cases with caudate atrophy, two had
Fig. 1 MRI scans of FTLD-FUS cases. a Patient 1 with severe atrophy (PD-weighted MR image). b Patient 2 with severe atrophy (PD-weighted
MR image). c Patient 3 with mild-moderate atrophy (FLAIR MR image). d Patient 4 with severe atrophy (T1-weighted MR image)
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a GRN mutation and had an age at onset[40 years, and the
third patient had FTLD-FUS with an age at onset of
49 years (Case 1). The interval between onset and time of
MRI scanning between cases with and without caudate
atrophy did not differ (36 months in cases with caudate
atrophy as well as in cases without caudate atrophy).
Seven of the eleven patients with a negative family
history, onset B40 years and bvFTD had caudate atrophy.
There were no MRIs available of the other four patients.
Pathology of FTLD-FUS
Brain weight, gross atrophy and depigmentation of the
substantia nigra are summarized in Table 2. The most
characteristic feature was the striking atrophy of the cau-
date in all four cases.
All four brains showed severe neuronal loss of CA1 and
subiculum consistent with hippocampal sclerosis, as well as
severe neuronal loss of the caudate nucleus. The frontal and/
or temporal cortices showed moderate-to-severe neuronal
loss in all, whereas the parietal cortex was mildly affected in
only one brain. The substantia nigra was severely affected
in all four brains. There was no involvement of the pons,
medulla oblongata, cerebellum, or spinal cord.
Immunohistochemistry revealed many ubiquitin, p62,
and FUS-positive, TDP-43-negative neuronal cytoplas-
matic inclusions (NCI) in the granular cells of the dentate
gyrus of the hippocampus, whereas the number of NCI and
dystrophic neurites (DN) in the frontotemporal cortex and
caudate nucleus was low. Several ubiquitin and FUS-
positive, p62 and TDP-43-negative neuronal intranuclear
inclusions (NII) of variable shapes (straight, worm-like, C-
shaped, or ring-like) were found in the granular cells of the
dentate gyrus in all four brains (Fig. 2a, c, d); two brains
also had NII in the CA4 pyramidal neurons, including one
with NII in CA3 (Case 1). Case 3 had NCI and NII in the
medulla oblongata. The antibody against the ubiquitin-
binding protein p62 gave positive staining of NCI and DN,
but not with NII (Fig. 2b). There were no inclusions found
in the substantia nigra, pons, medulla, or cerebellum of any
of the four brains. Immunostaining with AT-8, a-synuclein,
and a-internexin was negative in all cases.
Discussion
This study showed a frequency of FTLD-FUS of six per-
cent of all our pathologically proven FTLD cases, and 11
percent of the FTLD-U cases. We estimated a frequency of
FTLD-FUS of three percent in the total series of patients
with clinical FTD, based on the clinical variables age at
onset, family history, and clinical subtype. All four FTLD-
FUS cases presented with severe behavioural changes,
young age at onset, negative family history, and caudate
atrophy on MRI. FTLD-FUS cases were pathologically
characterized by striking atrophy of the caudate nucleus,
ubiquitin and FUS-positive, p62 and TDP-43-negative NII
with remarkable morphology.
The present observation of three percent of FTLD-FUS
in a large clinical cohort of FTD patients gives a frequency
estimation of this subtype for the first time. Of the four
FTLD-FUS patients, three had an age at onset B40 years,
negative family history, and clinical presentation of
bvFTD. As 11 patients within the age group B40 years of
our cohort meet the combination of these features, this
suggests an even higher frequency in this age group. Our
observed age distribution is in line with that of the other
reported series of FTLD with TDP-43 negative inclusions
(28 to 63 years) [4–6]. Delusions and hallucinations in the
Table 2 Anatomical distribution and severity of degeneration in
FTLD-FUS cases
Case 1 Case 2 Case 3 Case 4
Brain weight (g) 1,171 868 1,040 870
Gross atrophy/
depigmentation
FT?? FT?? FT?? FT??
Hipp?? Hipp?? Hipp?? Hipp??
Str?? Str?? Str?? Str??
SN? SN?? SN?
Frontal
Degeneration ?? ? ?? ??
NCI/DN ? ? ? ?
NII – – ? –
Temporal
Degeneration ?? ?? ?? ??
NCI/DN ? ? ?
NII – – – –
Hippocampus
Degeneration ?? ?? ?? ??
NCI ?? ?? ?? ?
NII ? ? ? ?
Striatum
Degeneration ?? ?? ?? ??
NCI/DN ? ? ? ?
NII – – – –
Substantia nigra
Degeneration ?? ?? ?? ??
NCI – – – –
NCI and DNs stained positive for ubiquitin, p62, and FUS immuno-
histochemistry only. NII stained positive for ubiquitin, and FUS
immunohistochemistry only
F frontal, T temporal, Hipp hippocampus, Str striatum, SN substantia
nigra, NCI neuronal cytoplasmatic inclusions, NII neuronal intranu-
clear inclusions, DN dystrophic neurites, – absent, ? mild, ??
moderate-severe
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present cases may be discriminative features of this type of
FTLD, as their occurrence is uncommon for the total FTD
group [13]. The initial diagnosis of a primary psychiatric
disorder has been considered in one of the present patients
[14], as well as in several other recently reported cases
[4, 5]. The occurrence of disinhibition and obsessive
compulsive behaviour was reported in the present cases,
while aggressive behaviour was reported in others [4].
Although we did not have pathological verification of
four other patients, the combination of age at onset
B40 years, negative family history, presence of severe
behavioural changes and caudate atrophy is highly sug-
gestive of FTLD-FUS. Our suggested prevalence of three
percent could be an underestimate, as *30 percent of all
cases described so far had an age at onset above 40 years,
and not all patients in our cohort had an available MRI to
semi-quantitatively score the caudate atrophy [4–6].
The observation of caudate atrophy on MRI in our
FTLD-FUS cases during life has not been reported so far,
but is in line with the presence of caudate atrophy and
severe neuron loss at neuropathological examination.
Neuroimaging features during life were not explicitly
mentioned in three pathological studies on TDP-43-nega-
tive FTLD-U cases (FTLD-FUS in the new nomenclature)
[15–17]. Although smaller caudate volumes may be seen in
the end-stage of FTD [18, 19], severe caudate atrophy was
already detectable in the early disease stage of the present
FTLD-FUS cases. Prominent caudate atrophy is charac-
teristic for Huntington’s disease, but chorea or other
extrapyramidal signs were absent in the present cases.
The occurrence of FTLD-FUS in 11% of our FTLD-U
cases lies between the frequencies reported in other series
[4–6], and emphasizes the idea that alternative pathophysi-
ological mechanisms exist in the clinicopathological spec-
trum of FTLD and motor neuron disease. The FUS protein
containing 526 amino-acids has structural similarities with
TDP-43 and is involved in DNA repair and the regulation of
transcription, RNA splicing, and export to cytoplasm [7, 20, 21].
Mutations in the FUS gene located on chromosome 16 have
recently been identified in familial ALS with ubiquitin and
FUS-positive, TDP-43-negative inclusions [20, 21].
The TDP-43-negative, FUS-positive cytoplasmatic
inclusions have also been found in neuronal intermediate
filament inclusion disease (NIFID) cases [22], whereas
their presence has yet to be investigated in other related
disorders: FTLD caused by CHMP2B mutations, baso-
philic inclusion body disease (BIBD), and ALS due to
SOD1 mutations [23–26].
The remarkable vermiform or C-shaped morphology of
the NII reported in all cases seems to be pathognomic for
FTLD-FUS and differs from the lentiform or cat-eye
shaped NII in GRN mutations [4–6, 27–29]. Moreover, NII
of GRN mutations shows a different immunohistochemical
pattern with TDP-43 positive and FUS negative staining.
The relevance of exclusive p62-positive staining of the
cytoplasmatic inclusions (and not of NII) still has to be
determined. The question is whether the p62 protein is
merely entrapped in these inclusions or plays a pathophysi-
ological role in these disorders. The recent finding of accu-
mulation of hyperphosphorylated tau and neurodegeneration
Fig. 2 Immunohistochemistry
of the FTLD-FUS cases.
Ubiquitin-positive neuronal
intranuclear inclusions (NII) in
the granular cells of the dentate
gyrus, which are worm-like (a).
Only the ubiquitin-positive
neuronal cytoplasmatic
inclusions (NCI) stained
positive with p62 (b); NII did
not. TDP-43-
immunohistochemistry stained
only normal nuclei, and stained
neither ubiquitin-positive NCI
nor NII (c). NCI as well as NII
stained positive with FUS
antibody (d). Scale bar 50 lm
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in mice with genetic inactivation of the p62 gene supports the
latter hypothesis [30].
A major drawback of the present study is the absence of
a quantitative assessment of caudate atrophy on MRI [18].
Future prospective follow-up studies with voxel-based
morphometry of the caudate nucleus on MRI are needed to
determine the progression of caudate atrophy over time in
FTLD-FUS.
In conclusion, FTLD-FUS is estimated to account for
three percent of our series of clinical FTD. Age at onset
B40 years, negative family history, bvFTD and caudate
atrophy on MRI could be useful clinical predictors of
FTLD-FUS as an underlying pathology in patients with
clinical FTD. Larger samples of FTLD-FUS cases are
needed to verify and to add new predictors for this clini-
copathological subtype.
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